← Back to Search

Other

SM17 for Asthma

Phase 1
Waitlist Available
Research Sponsored by SinoMab BioScience Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up until follow-up (fu) visit/early termination (et) visit (14 and 28 days post-last dose)

Summary

This trial tests a new drug called SM17 given through an IV in healthy people. It aims to see if SM17 is safe and how the body processes it.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~until follow-up (fu) visit/early termination (et) visit (14 and 28 days post-last dose)
This trial's timeline: 3 weeks for screening, Varies for treatment, and until follow-up (fu) visit/early termination (et) visit (14 and 28 days post-last dose) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Part A and Part B: Number of subjects with adverse events
Other study objectives
Pharmacokinetic parameters of SM17 in healthy subjects

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug SM17Experimental Treatment1 Intervention
Peripheral intravenous injection
Group II: Drug PlaceboPlacebo Group1 Intervention
Peripheral intravenous injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SM17
2022
Completed Phase 1
~80

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

SinoMab BioScience LtdLead Sponsor
4 Previous Clinical Trials
754 Total Patients Enrolled

Media Library

Placebo (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05332834 — Phase 1
Asthma Research Study Groups: Drug Placebo, Drug SM17
Asthma Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT05332834 — Phase 1
Placebo (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05332834 — Phase 1
~23 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top